BERWYN, PA — AscellaHealth has announced the promotion of Donovan Quill to Chief Strategy Officer, Life Sciences, and Bob Gilkin, RPh, MBA, to Chief Commercial and Growth Officer. Alongside their leadership roles at AscellaHealth, both will also contribute to Actum Pharma, an affiliate organization dedicated to supporting the development and market success of innovative therapies.
The dual appointments mark a strategic effort to bridge operational gaps for pharmaceutical companies and biopharma startups. Bill Oldham, president and chairman of AscellaHealth, explained, “By integrating the strengths of AscellaHealth and Actum, we can provide valuable opportunities for companies launching new therapies or repositioning existing ones for market growth.”
Quill, a rare disease advocate driven by personal experience, highlighted his commitment to ensuring therapies reach the right patients. “Taking on a leadership role with Actum Pharma provides an exciting opportunity for me to help clinical-stage companies while continuing my work with in-market therapies that require specialty distribution and patient services,” he noted.
Gilkin, with roots as a pharmacist, emphasized the importance of innovative strategies to complement scientific breakthroughs. “This dual appointment allows us to help remove bottlenecks for clients and develop models to advance future therapies,” he shared.
With these leadership advancements, AscellaHealth and Actum Pharma aim to streamline access to life-changing treatments, fostering new opportunities for growth across the pharmaceutical industry.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.